TYK Medicines will cooperate with Professor Ying Cheng of Jilin Provincial Cancer Hospital to carry out Phase I clinical trial of TY-1091

TYK Medicines will cooperate with Professor Ying Cheng of Jilin Provincial Cancer Hospital to carry out Phase I clinical trial of TY-1091

Dr. Shaoqing Chen was Selected as the First Batch of the “South Taihu Lake Elite Plan” Leading Innovative Talents in Huzhou City in 2022

Dr. Shaoqing Chen was Selected as the First Batch of the "South Taihu Lake Elite Plan" Leading Innovative Talents in Huzhou City in 2022

TYK Medicines collaborates with Syneos Health to conduct TY-2136b Phase I clinical trial in the United States

TY-9591 Phase II study in patients with EGFRm NSCLC and brain metastases was successfully initiated at the Affiliated Cancer Hospital of Chinese Academy of Medical Sciences

TYK Medicines Successfully Passed the Postdoctoral Workstation Certification

TYK Medicines Completes Series C Financing of 330 Million Yuan, Led by Huge Capital